114 results
8-K
EX-1.1
FATE
Fate Therapeutics Inc
20 Mar 24
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
5:32pm
and the Prospectus), or any change in the short-term indebtedness, long-term indebtedness (other than as a result of the conversion of convertible
424B5
FATE
Fate Therapeutics Inc
20 Mar 24
Prospectus supplement for primary offering
5:30pm
holdings;
persons that own, or are deemed to own, more than five percent of our common stock;
former citizens or long-term residents of the United … . However, with respect to dividends received by individuals, such dividends are generally taxed at the lower applicable long-term capital gains rates
8-K
EX-99.1
rn052nktd57t
26 Feb 24
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4:03pm
8-K
EX-99.1
45b1w
8 Nov 23
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
4:03pm
8-K
EX-99.1
pvbqdph f4mza9vp
8 Aug 23
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
4:07pm
8-K
EX-99.1
edd0it49yq
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm
8-K
EX-99.1
uqhz0s9hrk9j7y05b
3 Nov 22
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
EX-99.1
rtkohpx687ojcojz
3 Aug 22
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm